Cancer research gap exposed as study reveals melanoma's unexpected relationship with ageing

Cancer is widely known to become more common with age and more difficult to treat in older adults, yet the majority of cancer research studies fail to reflect that reality.

Now, new findings are challenging long-held assumptions about how melanoma behaves as patients age — and the results are striking.

Cancer spread peaks in middle age, then declines

A study has revealed that melanoma may be at its most dangerous during middle age, as the disease appears to briefly gain the upper hand against the immune system before losing ground again in extreme old age.

In what researchers have described as a surprising discovery, cancer spread was found to be lowest in young mice, surged significantly in middle-aged mice, and then fell again in very old mice.

The findings suggest that melanoma does not become steadily more dangerous with advancing age, as scientists had previously assumed.

Gamma delta T cells at the heart of the pattern

Researchers believe a specialised group of immune cells known as gamma delta (γδ) T cells may help account for this unexpected pattern. These cells function as an early line of defence, helping to prevent cancer from spreading throughout the body.

Both young mice and very old mice were found to have higher levels of these protective immune cells, and their tumours were more likely to remain dormant or spread less aggressively.

Middle-aged mice, however, presented a markedly different picture — they had fewer γδ T cells, and melanoma was considerably more likely to spread to organs such as the lungs and liver.

A critical gap in cancer research

The findings also draw attention to a significant blind spot in how cancer research is conducted.

Fewer than ten per cent of mouse experiments use aged animals, with researchers typically relying on mice that correspond roughly to humans in their early twenties.

That gap, the study suggests, may help explain why many cancer therapies that perform well in laboratory settings ultimately fail when tested in human clinical trials — where the patients are predominantly older.

The new findings underscore the importance of including older animals in pre-clinical cancer research to better reflect the population most affected by the disease.

About the research

Research materials were provided by Temple University Health System, with the findings contributed by Fox Chase Cancer Center.

The study was presented at the American Association for Cancer Research annual meeting and published in the journal Cancer Research, 2026, under the title "Role of Aging on the γδ T-cells in Metastatic Cutaneous Melanoma Progression."